Amadix: Funding, Investors & Team (Sep 2026)
Amadix develops and commercializes breakthrough discoveries in cancer diagnosis with a clear commercial rationale, addressing unmet medical needs in oncology. After analytical validation and demonstration of clinical validity and utility through international multicentre studies, the products will be commercialized worldwide. The most advanced product developed by Amadix is Colofast, an innovative non-invasive screening signature for colorectal cancer (CRC) and advanced adenoma diagnosis in blood designed to solve a significant health priority: the high mortality rate due to colon cancer worldwide (around half of the diagnosed patients). Amadix team consist of industry veterans with robust expertise in the Oncology Diagnostic area. They are a top level management team with international experience in cancer diagnostics, the pharmaceutical industry, the biotechnology sector and intellectual property. Amadix also has independent board members with international profiles and many years of experience in oncology and diagnostics, who advise the management team on strategy, commercialization and business development in Europe and the US.
Amadix has raised $18.0M across 2 funding rounds on record, the most recent an undisclosed round of $15.5M announced in Feb 2025.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Amadix Company Profile and Key Stats
Latest funding round on record: Feb 2025.
Amadix Funding Rounds
Amadix raised $2.5M in a Grant announced in Jan 2022.
3.1 years later, an undisclosed round of $15.5M was announced in Feb 2025.
Amadix Founders and Leadership Team
Contact details for the Amadix team: 1 of 1 has an email address on file.
Start 14-day free trial →Amadix Funding Compared to Other Biotechnology Startups
Amadix's latest round of $15.5M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Amadix in Biotechnology and Madrid
Companies Similar to Amadix
Connecta Therapeutics is a biotechnology company that develops new treatments for unresolved medical needs of…
iPremom is a healthcare technology company that develops molecular diagnostic solutions for the early…
Gate2Brain is a biotech company focused on the development of therapeutics that efficiently cross biological…
Ona Therapeutics is a biotech company that specializes in the discovery and development of therapeutic…
IMPETUX develops and markets patented technology to characterise the mechanical properties of living tissues…
Molecular Gate refer to an innovative class of small-molecule drugs developed by Gate Bioscience. These drugs…
Modern medicine fails because it studies life in static environments. 60Nd revolutionizes the field with…
Devicare designs point-of-care medical devices that monitor, diagnose and treat chronic diseases. The…
Universal Diagnostics S.A. (UDX) is a company in Spain that specializes in in-vitro diagnostics. Their focus…
Phyture Biotech originated as a spin-off of the Faculty of Pharmacy at the University of Barcelona, founded…
Polimerbio offers sanitary product design and development based on biocompatible polymers, particularly…
Overture Life is a biotechnology company that specializes in developing automated technologies for assisted…
Amadix Funding FAQs
What does Amadix do?
Amadix develops and commercializes breakthrough discoveries in cancer diagnosis with a clear commercial rationale, addressing unmet medical needs in oncology. After analytical validation and demonstration of clinical validity and utility through international multicentre studies, the products will be commercialized worldwide. The most advanced product developed by Amadix is Colofast, an innovative non-invasive screening signature for colorectal cancer (CRC) and advanced adenoma diagnosis in blood designed to solve a significant health priority: the high mortality rate due to colon cancer worldwide (around half of the diagnosed patients). Amadix team consist of industry veterans with robust expertise in the Oncology Diagnostic area. They are a top level management team with international experience in cancer diagnostics, the pharmaceutical industry, the biotechnology sector and intellectual property. Amadix also has independent board members with international profiles and many years of experience in oncology and diagnostics, who advise the management team on strategy, commercialization and business development in Europe and the US.
How much funding has Amadix raised?
Amadix has raised $18.0M across 2 rounds on record. The most recent is an undisclosed round of $15.5M announced in Feb 2025.
When did Amadix last raise funding?
Amadix's most recent funding round on record is an undisclosed round of $15.5M, announced in Feb 2025.
Who founded Amadix?
FundedIQ lists Rocio Arroyo (Founder) at Amadix.
Where is Amadix headquartered?
Amadix is based in Madrid, Spain.
How many employees does Amadix have?
Amadix is in the 11-50 employee band.
How does Amadix's funding compare to other Biotechnology startups?
Amadix's latest round of $15.5M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,183 tracked companies over the last two years.
About FundedIQ's Amadix Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Amadix is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.